Literature DB >> 24569963

Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation.

Cinzia Puppin1, Cosimo Durante, Marialuisa Sponziello, Antonella Verrienti, Valeria Pecce, Elisa Lavarone, Federica Baldan, Antonio Francesco Campese, Amelie Boichard, Ludovic Lacroix, Diego Russo, Sebastiano Filetti, Giuseppe Damante.   

Abstract

Abnormal expression of non-coding micro RNA (miRNA) has been described in medullary thyroid carcinoma (MTC). Expression of genes encoding factors involved in miRNA biogenesis results often deregulated in human cancer and correlates with aggressive clinical behavior. In this study, expression of four genes involved in miRNA biogenesis (DICER, DROSHA, DCGR8, and XPO5) was investigated in 54 specimens of MTC. Among them, 33 and 13 harbored RET and RAS mutations, respectively. DICER, DGCR8, and XPO5 mRNA levels were significantly overexpressed in MTC harboring RET mutations, in particular, in the presence of RET634 mutation. When MTCs with RET and RAS mutations were compared, only DGCR8 displayed a significant difference, while MTCs with RAS mutations did not show significant differences with respect to non-mutated tumors. We then attempted to correlate expression of miRNA biogenesis genes with tumor aggressiveness. According to the TNM status, MTCs were divided in two groups and compared (N0 M0 vs. N1 and/or M1): for all four genes no significant difference was detected. Cell line experiments, in which expression of a RET mutation is silenced by siRNA, suggest the existence of a causal relationship between RET mutation and overexpression of DICER, DGCR8, and XPO5 genes. These findings demonstrate that RET- but not RAS-driven tumorigenic alterations include abnormalities in the expression of some important genes involved in miRNA biogenesis that could represent new potential markers for targeted therapies in the treatment of RET-mutated MTCs aimed to restore the normal miRNA expression profile.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24569963     DOI: 10.1007/s12020-014-0204-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  42 in total

1.  Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.

Authors:  V Besset; R P Scott; C F Ibáñez
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

2.  Reduced expression of Dicer associated with poor prognosis in lung cancer patients.

Authors:  Yoko Karube; Hisaaki Tanaka; Hirotaka Osada; Shuta Tomida; Yoshio Tatematsu; Kiyoshi Yanagisawa; Yasushi Yatabe; Junichi Takamizawa; Shinichiro Miyoshi; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Sci       Date:  2005-02       Impact factor: 6.716

3.  Mutation screening of RET proto-oncogene in a family with medullary thyroid carcinoma, marfanoid habitus and pheochromocytoma; from clinically MEN2B to genetically MEN2A syndrome.

Authors:  Shirin Hasani-Ranjbar; Mahsa M Amoli
Journal:  Endocrine       Date:  2012-01-31       Impact factor: 3.633

4.  MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets.

Authors:  Deepak Abraham; Nicole Jackson; Justin S Gundara; JingTing Zhao; Anthony J Gill; Leigh Delbridge; Bruce G Robinson; Stan B Sidhu
Journal:  Clin Cancer Res       Date:  2011-05-27       Impact factor: 12.531

Review 5.  XL184 (cabozantinib) for medullary thyroid carcinoma.

Authors:  Cosimo Durante; Diego Russo; Antonella Verrienti; Sebastiano Filetti
Journal:  Expert Opin Investig Drugs       Date:  2011-03       Impact factor: 6.206

6.  A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells.

Authors:  Sonia A Melo; Catia Moutinho; Santiago Ropero; George A Calin; Simona Rossi; Riccardo Spizzo; Agustin F Fernandez; Veronica Davalos; Alberto Villanueva; Guillermo Montoya; Hiroyuki Yamamoto; Simo Schwartz; Manel Esteller
Journal:  Cancer Cell       Date:  2010-10-19       Impact factor: 31.743

7.  Dicer, Drosha, and outcomes in patients with ovarian cancer.

Authors:  William M Merritt; Yvonne G Lin; Liz Y Han; Aparna A Kamat; Whitney A Spannuth; Rosemarie Schmandt; Diana Urbauer; Len A Pennacchio; Jan-Fang Cheng; Alpa M Nick; Michael T Deavers; Alexandra Mourad-Zeidan; Hua Wang; Peter Mueller; Marc E Lenburg; Joe W Gray; Samuel Mok; Michael J Birrer; Gabriel Lopez-Berestein; Robert L Coleman; Menashe Bar-Eli; Anil K Sood
Journal:  N Engl J Med       Date:  2008-12-18       Impact factor: 91.245

8.  Current management of medullary thyroid cancer.

Authors:  Rebecca S Sippel; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Oncologist       Date:  2008-05

9.  Dicer is regulated by cellular stresses and interferons.

Authors:  Jennifer L Wiesen; Thomas B Tomasi
Journal:  Mol Immunol       Date:  2008-12-31       Impact factor: 4.407

10.  A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.

Authors:  Maria D Castellone; Antonella Verrienti; Deva Magendra Rao; Marialuisa Sponziello; Dora Fabbro; Magesh Muthu; Cosimo Durante; Marianna Maranghi; Giuseppe Damante; Stefano Pizzolitto; Giuseppe Costante; Diego Russo; Massimo Santoro; Sebastiano Filetti
Journal:  Clin Endocrinol (Oxf)       Date:  2010-10       Impact factor: 3.478

View more
  18 in total

Review 1.  Management of hereditary medullary thyroid carcinoma.

Authors:  Theodora Pappa; Maria Alevizaki
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

Review 2.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

Review 3.  PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.

Authors:  Gloria Irene Manfredi; Alessandra Dicitore; Germano Gaudenzi; Michele Caraglia; Luca Persani; Giovanni Vitale
Journal:  Endocrine       Date:  2014-08-13       Impact factor: 3.633

Review 4.  Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.

Authors:  Ying-Hsia Chu; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

5.  EIF2C, Dicer, and Drosha are up-regulated along tumor progression and associated with poor prognosis in bladder carcinoma.

Authors:  Zhe Zhang; Guojun Zhang; Chuize Kong; Jianbin Bi; Daxin Gong; Xiuyue Yu; Du Shi; Bo Zhan; Peng Ye
Journal:  Tumour Biol       Date:  2015-02-06

6.  Cancer stem cells as a potential therapeutic target in thyroid carcinoma.

Authors:  Luisa Vicari; Cristina Colarossi; Dario Giuffrida; Ruggero De Maria; Lorenzo Memeo
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

Review 7.  Non-Coding RNAs in Thyroid Cancer.

Authors:  Ranran Zhang; Heather Hardin; Jidong Chen; Zhenying Guo; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

8.  MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome.

Authors:  Imen Medimegh; Ines Omrane; Maud Privat; Nancy Uhrhummer; Hajer Ayari; Fadoua Belaiba; Farhat Benayed; Khaled Benromdhan; Sylvie Mader; Ives-Jean Bignon; Amel Benammar Elgaaied
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

Review 9.  A Brief Review on The Molecular Basis of Medullary Thyroid Carcinoma.

Authors:  Masoumeh Mohammadi; Mehdi Hedayati
Journal:  Cell J       Date:  2016-09-26       Impact factor: 2.479

Review 10.  Dysregulation of miRNAs in bladder cancer: altered expression with aberrant biogenesis procedure.

Authors:  Fan Dong; Tianyuan Xu; Yifan Shen; Shan Zhong; Shanwen Chen; Qiang Ding; Zhoujun Shen
Journal:  Oncotarget       Date:  2017-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.